Bluesphere Bio

BlueSphere Bio is the first translational stand-alone company spun out of UPMC Enterprises, the commercialization arm of the Pittsburgh health system giant. The company was founded upon the unique, advanced TCR discovery platform - TCXpress™, designed to isolate and functionally characterize TCRs with speed, sensitivity and efficiency. BlueSphere anticipates filing its first IND application in 2022 for a novel TCR T-cell therapy for patients with high-risk leukemias, including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in the context of allogeneic stem cell transplantation (alloSCT). Concurrent with its pursuit of hematologic cancers, BlueSphere is pursuing additional programs in solid tumors using NEOXpress™, a proprietary patient-specific neoantigen discovery platform, to target patient-specific neoantigens, and anticipates virtual patient data from multiple tumor types by the end of 2022.